Abstract
Background
The objective of this study was to investigate the relationship between nodal tumor burden and the outcomes of recurrence and survival in sentinel node-positive melanoma patients.
Methods
We reviewed a series of sentinel node-positive patients with primary cutaneous melanoma treated with completion lymph node dissection (CLND). Microscopic nodal tumor deposits were counted and measured with an ocular micrometer. Various measures of tumor burden and traditional melanoma prognostic indicators were studied in multivariate Cox regression models.
Results
Sentine lympho node and CLND specimens were evaluated in 90 node-positive patients. The diameter of the largest lymph node tumor nodule and the total lymph node tumor volume were significant predictors of recurrence (two-sideP<.0001 for both) and survival (two-sidedP=.0018 andP=.0002, respectively). A tumor deposit diameter of 3 mm was identified as the most significant cut point predictive of recurrence (P<.0001; hazard ratio, 5.18) and survival (P<.0001; hazard ratio, 5.43). The 3-year survival probability was .86 for patients with largest tumor deposit diameters of ≤3 mm and was .27 for patients with largest deposit diameters >3 mm (P<.0001).
Conclusions
Microstaging of melanoma sentinel lymph node/CLND specimens by using the diameter of the largest tumor deposit is a highly significant predictor of early relapse and survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Commitee on Cancer staging system for cutaneous melaroma.J Clin Oncol 2001;19:3635–48.
Morton DL, Wen DR, Wong JH, et al. Technical details of intra-operative lymphatic mapping for early stage melanoma.Arch Surg 1992;127:392–9.
Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J Clin Oncol 2001;19:3622–34.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.J Clin Oncol 1999;17:976–83.
Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes.Cancer 1999;86: 617–27.
Wagner JD, Davidson D, Coleman JJ III, et al. Lymph node tumor volumes in patients undergoing sentinel lymph node biopsy for cutaneous melanoma.Ann Surg Oncol 1999;6:398–404.
Wagner JD, Gordon MS, Chuang T-Y, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.Cancer 2000;89:453–62.
Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node-positive patients.Ann Surg 1990;212:125–31.
Coit DG, Rogatko A, Brennan MF. Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes. A multivariate analysis.Ann Surg 1991;214:627–36.
Drepper H, Biess B, Hofherr B, et al. The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide.Cancer 1993;71:1239–46.
Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma.J Clin Oncol 1995;13:2361–8.
Joseph E, Brobeil A, Glass F, et al. Results of complete lymph node dissection in 83 patients with positive sentinel nodes.Ann Surg Oncol 1998;5:119–25.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ranieri, J.M., Wagner, J.D., Azuaje, R. et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Annals of Surgical Oncology 9, 975–981 (2002). https://doi.org/10.1007/BF02574515
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02574515